ARROWHEAD PHARMACEUTICALS, INC. quarterly report, Q3 FY2020

Arrowhead Pharmaceuticals, Inc. — Form 10-Q Summary

Business context and period: Arrowhead develops RNAi-based medicines. This unaudited filing covers the fiscal third quarter and nine months ended June 30, 2020; the fiscal year ends September 30. Its pipeline includes company-developed and partnered clinical candidates.

Financial performance and position

MetricThree months ended June 30, 2020Three months ended June 30, 2019Nine months ended June 30, 2020Nine months ended June 30, 2019
Revenue$27.4 million$42.7 million$80.4 million$125.5 million
Operating income (loss)($15.9 million)$18.6 million($43.0 million)$51.6 million
Net income (loss)($13.6 million)$20.3 million($36.1 million)$56.3 million
Diluted earnings (loss) per share($0.13)$0.21($0.36)$0.58
  • Quarterly revenue declined about 36% year over year; nine-month revenue declined about 36%. Management attributed the decline primarily to the timing of progress recognized under the Janssen/JJDC arrangements, partly offset by $20 million of Amgen-related revenue in the 2020 periods.
  • Research and development expense was $32.6 million for the quarter and $85.4 million for nine months, up 69% and 48%, respectively. General and administrative expense was $10.7 million and $38.0 million, up 123% and 133%. Higher pipeline activity, headcount, and stock-based compensation contributed to the increases.
  • Operating margin, calculated as operating income or loss divided by revenue, was approximately (58%) for the quarter and (54%) for nine months, versus approximately 44% and 41% in the comparable 2019 periods. The filing does not present a gross margin or cost-of-revenue line.
  • Operating cash use was $84.5 million for the nine months, compared with $159.2 million of cash provided in 2019. Investing activities used $174.9 million, mainly for purchases of fixed-income investments and property and equipment. Financing provided $256.9 million, chiefly from the December 2019 stock offering.
  • At June 30, cash and cash equivalents were $219.3 million, short-term investments $67.7 million, and long-term investments $177.5 million. Total cash and investments were approximately $464.6 million. Current assets were $315.2 million; current liabilities were $42.8 million.
  • The balance sheet reports $21.4 million of lease liabilities, including current and long-term portions, and no notes payable balance. Total stockholders’ equity was $492.6 million. The company issued 4.6 million shares in December 2019 and received $250.5 million net proceeds.

Material changes, outlook, and risks

  • Revenue fell as a greater portion of Janssen/JJDC consideration had been recognized in the prior-year period. Janssen-related revenue was $6.9 million in the quarter and $57.9 million for nine months, versus $42.3 million and $124.8 million in 2019. The company reported $26.3 million of current deferred revenue related to the Janssen arrangement.
  • Amgen initiated a Phase 2 study in July 2020, which the filing says will result in a $20 million milestone payment. The filing also reports $20 million of Amgen-related revenue and receivable at June 30; investors should verify the timing and conditions associated with recognition and payment.
  • Management expects current cash and investment resources to fund operations for at least the next 12 months. It anticipates increased clinical and related costs as candidates advance, and said clinical-trial expenses are expected to rise as programs progress.
  • COVID-19 had not significantly affected reported results, but enrollment in two ARO-AAT studies was temporarily paused and resumed during the quarter. Further disruption to trial enrollment, sites, suppliers, employees, or timelines remained uncertain.
  • As of June 30, estimated purchase commitments were $83.0 million, including $20.5 million expected in fiscal 2020. Third-party technology licenses may also require milestone payments potentially in the mid- to upper-double-digit millions and royalties if products are commercialized. No contingent liabilities were recorded for litigation at June 30.
  • Effective August 5, 2020, after quarter-end, Arrowhead established a $250 million at-the-market equity facility; no shares had been sold under it as of the filing. The facility could provide capital but may dilute existing shareholders.

Most important facts for investors to verify

  • Trial progress, safety, and enrollment updates across ARO-AAT, ARO-HSD, ARO-APOC3, ARO-ANG3, ARO-HIF2, ARO-ENaC, and partnered programs.
  • Revenue-recognition assumptions and milestone payment timing under the Janssen and Amgen agreements, including the $20 million Amgen milestone.
  • Cash burn relative to the approximately $464.6 million cash-and-investment balance, planned clinical spending, and $83.0 million of purchase commitments.
  • Potential share dilution from equity compensation and any future use of the $250 million ATM facility.
  • COVID-19 effects on trials and supply, and the clinical, regulatory, manufacturing, and financing risks described in the filing.